Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
1999 2
2000 2
2001 3
2002 4
2003 3
2004 3
2005 4
2006 5
2007 6
2008 25
2009 29
2010 45
2011 63
2012 67
2013 84
2014 98
2015 134
2016 143
2017 131
2018 142
2019 138
2020 159
2021 162
2022 164
2023 159
2024 63

Text availability

Article attribute

Article type

Publication date

Search Results

1,638 results

Results by year

Filters applied: . Clear all
Page 1
Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease.
Zuna J, Hovorkova L, Krotka J, Koehrmann A, Bardini M, Winkowska L, Fronkova E, Alten J, Koehler R, Eckert C, Brizzolara L, Trkova M, Stuchly J, Zimmermann M, De Lorenzo P, Valsecchi MG, Conter V, Stary J, Schrappe M, Biondi A, Trka J, Zaliova M, Cazzaniga G, Cario G. Zuna J, et al. Leukemia. 2022 Dec;36(12):2793-2801. doi: 10.1038/s41375-022-01668-0. Epub 2022 Aug 6. Leukemia. 2022. PMID: 35933523
Recently, we defined "CML-like" subtype of BCR::ABL1-positive acute lymphoblastic leukemia (ALL), resembling lymphoid blast crisis of chronic myeloid leukemia (CML). ...Moreover, in the typical ALL, risk-prediction could be further improved by considering ini …
Recently, we defined "CML-like" subtype of BCR::ABL1-positive acute lymphoblastic leukemia (ALL), resembling lymphoid blast cr …
Digital PCR for BCR-ABL1 Quantification in CML: Current Applications in Clinical Practice.
Kockerols CCB, Valk PJM, Levin MD, Pallisgaard N, Cornelissen JJ, Westerweel PE. Kockerols CCB, et al. Hemasphere. 2020 Nov 24;4(6):e496. doi: 10.1097/HS9.0000000000000496. eCollection 2020 Dec. Hemasphere. 2020. PMID: 33283168 Free PMC article. Review.
Molecular monitoring of the BCR-ABL1 transcript for patients with chronic phase chronic myeloid leukemia (CML) has become increasingly demanding. ...We reviewed the current use of digital PCR (dPCR) as a promising alternative for response monitoring in CML. d …
Molecular monitoring of the BCR-ABL1 transcript for patients with chronic phase chronic myeloid leukemia (CML) has become incr …
Response and Resistance to BCR-ABL1-Targeted Therapies.
Braun TP, Eide CA, Druker BJ. Braun TP, et al. Cancer Cell. 2020 Apr 13;37(4):530-542. doi: 10.1016/j.ccell.2020.03.006. Cancer Cell. 2020. PMID: 32289275 Free PMC article. Review.
Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine kinase, has served as a paradigm for successful application of molecularly targeted cancer therapy. ...Some patients develop TKI resistance without known resistance mutations, w …
Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine kinase, has served as a paradigm for …
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
Jabbour E, Kantarjian H. Jabbour E, et al. Am J Hematol. 2022 Sep;97(9):1236-1256. doi: 10.1002/ajh.26642. Epub 2022 Jul 6. Am J Hematol. 2022. PMID: 35751859 Free article.
It accounts for approximately 15% of newly diagnosed cases of leukemia in adults. DIAGNOSIS: CML is characterized by a balanced genetic translocation, t (9;22) (q34;q11.2), involving a fusion of the Abelson gene (ABL1) from chromosome 9q34 with the breakpoint cluste …
It accounts for approximately 15% of newly diagnosed cases of leukemia in adults. DIAGNOSIS: CML is characterized by a balanced genet …
Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation.
Burslem GM, Schultz AR, Bondeson DP, Eide CA, Savage Stevens SL, Druker BJ, Crews CM. Burslem GM, et al. Cancer Res. 2019 Sep 15;79(18):4744-4753. doi: 10.1158/0008-5472.CAN-19-1236. Epub 2019 Jul 16. Cancer Res. 2019. PMID: 31311809 Free PMC article.
GMB-475 degraded BCR-ABL1 and reduced cell viability in primary CML stem cells. Together, these findings suggest that combined BCR-ABL1 kinase inhibition and protein degradation may represent a strategy to address BCR-ABL1-dependent drug resistance, an …
GMB-475 degraded BCR-ABL1 and reduced cell viability in primary CML stem cells. Together, these findings suggest that combined …
Molecular biology of bcr-abl1-positive chronic myeloid leukemia.
Quintás-Cardama A, Cortes J. Quintás-Cardama A, et al. Blood. 2009 Feb 19;113(8):1619-30. doi: 10.1182/blood-2008-03-144790. Epub 2008 Sep 30. Blood. 2009. PMID: 18827185 Free PMC article. Review.
Chronic myeloid leukemia (CML) has been regarded as the paradigmatic example of a malignancy defined by a unique molecular event, the BCR-ABL1 oncogene. Decades of research zeroing in on the role of BCR-ABL1 kinase in the pathogenesis of CML have culmi …
Chronic myeloid leukemia (CML) has been regarded as the paradigmatic example of a malignancy defined by a unique molecular event, the …
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions.
Osman AEG, Deininger MW. Osman AEG, et al. Blood Rev. 2021 Sep;49:100825. doi: 10.1016/j.blre.2021.100825. Epub 2021 Mar 16. Blood Rev. 2021. PMID: 33773846 Free PMC article. Review.
During the early (chronic) phase of CML (CP-CML), the myeloid cell compartment is expanded, but differentiation is maintained. ...The development of BCR-AB1 tyrosine kinase inhibitors (TKIs) revolutionized the treatment of CML and ignited the start of a new e …
During the early (chronic) phase of CML (CP-CML), the myeloid cell compartment is expanded, but differentiation is maintained. …
Beyond BCR::ABL1-The Role of Genomic Analyses in the Management of CML.
Branford S, Fernandes A, Shahrin N, Maqsood M, Shanmuganathan N, Wadham C. Branford S, et al. J Natl Compr Canc Netw. 2024 Feb;22(1):e237335. doi: 10.6004/jnccn.2023.7335. J Natl Compr Canc Netw. 2024. PMID: 38394774 Review.
Chronic myeloid leukemia (CML) is a model of genomically based diagnosis and management where BCR::ABL1 is successfully targeted by tyrosine kinase inhibitor (TKI) therapy in most patients. ...Is it time to integrate broader genomic screening into clinical managemen …
Chronic myeloid leukemia (CML) is a model of genomically based diagnosis and management where BCR::ABL1 is successfully target …
Chronic Myeloid Leukemia: Beyond BCR-ABL1.
Zhou T, Medeiros LJ, Hu S. Zhou T, et al. Curr Hematol Malig Rep. 2018 Dec;13(6):435-445. doi: 10.1007/s11899-018-0474-6. Curr Hematol Malig Rep. 2018. PMID: 30370478 Review.
PURPOSE OF REVIEW: In this review, we emphasize up-to-date practical cytogenetic and molecular aspects of chronic myeloid leukemia (CML) and summarize current knowledge on tyrosine kinase inhibitor (TKI) resistance and treatment response monitoring of CML. RECENT FI …
PURPOSE OF REVIEW: In this review, we emphasize up-to-date practical cytogenetic and molecular aspects of chronic myeloid leukemia (CML …
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
Jabbour E, Kantarjian H. Jabbour E, et al. Am J Hematol. 2020 Jun;95(6):691-709. doi: 10.1002/ajh.25792. Epub 2020 Apr 10. Am J Hematol. 2020. PMID: 32239758 Free article.
DISEASE OVERVIEW: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1-2 cases per 100 000 adults. It accounts for approximately 15% of newly diagnosed cases of leukemia in adults. DIAGNOSIS: CML is characterized by a balanced genet …
DISEASE OVERVIEW: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1-2 cases per 100 000 adults. …
1,638 results